Performance Status Scales in Cancer Care
Introduction to ECOG and KPS
- The ECOG scale is a 5-level ordered scale (0-4) that assesses functional status based on a patient's ability to perform daily activities and self-care, with higher scores indicating worse performance status, as recommended by the National Comprehensive Cancer Network 1, 2
- The KPS is an 11-level ordered scale ranging from 0 to 100 in increments of 10, assessing three core domains: activity level, ability to work, and self-care capacity, with higher scores indicating better functional status, according to Praxis Medical Insights 3
Clinical Thresholds for Treatment Decisions
- Patients with ECOG 0-1 are considered "high-functioning" or "good" performance status and are eligible for most clinical trials and aggressive treatment regimens, as stated by the Clinical Cancer Research journal 1, 2
- Patients with ECOG 2 have intermediate performance status and are increasingly included in clinical trials but historically excluded, and are eligible for systemic therapy with careful consideration, as recommended by the Clinical Cancer Research journal 1, 2
- Patients with ECOG ≥3 have poor performance status and should receive palliative/best supportive care only without systemic chemotherapy, according to the Journal of the National Comprehensive Cancer Network 4
- Patients with KPS ≥80 have good performance status and are eligible for three-drug chemotherapy regimens, as stated by Praxis Medical Insights 3
- Patients with KPS 60-70 have intermediate performance status and two-drug regimens are preferred over three-drug regimens, according to Praxis Medical Insights 3
- Patients with KPS ≥60 are eligible for systemic therapy with or without best supportive care, as recommended by the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 4, 3
- Patients with KPS <60 should receive best supportive care only without systemic chemotherapy, according to the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 4, 3
Limitations and Caveats
- Both ECOG and KPS are inherently subjective and susceptible to investigator bias, particularly for patients at borderline values between categories, as noted by the Clinical Cancer Research journal 1, 2
- Clinicians assign patients aged >65 higher numeric scores (worse performance status) than younger patients despite no objective difference in measured physical activity, representing systematic age-related bias, as stated by the Clinical Cancer Research journal and Praxis Medical Insights 1, 2, 3
- Performance status is less predictive of cancer-related outcomes in older adults compared to younger populations, according to the Clinical Cancer Research journal and Praxis Medical Insights 1, 2, 3
Prognostic Validity
- Both ECOG and KPS demonstrate strong prognostic validity, with lower performance status (ECOG 2-4, KPS ≤70) consistently correlated with lower overall survival and progression-free survival across multiple tumor types, as recommended by the Clinical Cancer Research journal 1, 2
ECOG Performance Status 0‑1: Eligibility, Trial Representation, and Treatment Decision‑Making
1. Eligibility for Aggressive Oncology Therapies
2. Representation in Clinical Trials
3. Prognostic and Toxicity Prediction Tools
4. Disease‑Specific Treatment Thresholds
5. Risk Stratification Incorporating ECOG
Systemic Therapy Recommendations for T4 Prostate Cancer Patients with ECOG Performance Status 1–2
Eligibility for Systemic Treatment
- Patients with T4 prostate cancer and an ECOG performance status of 1–2 are appropriate candidates for systemic therapy, but the choice of regimen should reflect their intermediate functional capacity. 10, 11
Treatment Options Based on ECOG Level
ECOG 1 (Good Performance)
- Individuals classified as ECOG 1 are deemed to have good performance status and are eligible for all standard FDA‑approved systemic agents for castration‑resistant disease, including docetaxel chemotherapy, abiraterone, enzalutamide, and comparable therapies. 10, 11
ECOG 2 (Intermediate Performance)
- Patients with ECOG 2 have intermediate performance status; they are increasingly enrolled in clinical trials and remain eligible for systemic therapy, but require heightened monitoring for treatment‑related toxicity. 12
ECOG 3–4 (Poor Performance)
- When performance status deteriorates to ECOG 3–4, the recommendation shifts to exclusive palliative care, avoiding systemic chemotherapy because it can postpone end‑of‑life care and introduce unnecessary toxicity without demonstrable benefit. 10, 11, 13
Clinical Factors Influencing Treatment Choice
- Regular use of opioid analgesics for cancer‑related pain designates a patient as symptomatic; this symptom status influences therapeutic selection even within the ECOG 1–2 range. 11, 14
- If the reduced performance status is primarily driven by tumor burden rather than comorbid conditions, systemic therapy may improve functional capacity, providing justification for its use. 13, 14
- Treatment decisions should be individualized after thorough discussion of risks, benefits, and quality‑of‑life considerations. 13, 14
Limitations of ECOG Assessment
- The ECOG scale is inherently subjective and prone to investigator bias, especially for patients whose scores fall near category boundaries. 12